The present invention relates to a novel synergistically active pharmaceutical compound (The Compound 1), such as a supramoleuclar complex or an adduct or a co-crystal, comprising Ticagrelor with salts of aspirin (acetyl salicylic acid). It also reports another novel pharmaceutical compound (The compound 2), such as a supramoleuclar complex or an adduct or a co-crystal comprising Ticagrelor and aspirin, which is free from methylene chloride. Both novel pharmaceutical compounds have distinct physico-chemical properties e.g. melting point, IR, powder XRD, DSC and TGA, which are different from the physico-chemical properties of its constituents. The present invention describes processes for the preparation of both novel pharmaceutical compounds (The Compound 1 and The Compound 2), their characterization, their use in pharmaceutical composition and finally their use in manufacture of medicament for use in prevention and/or treatment of arterial thrombotic complications in patients with coronary artery, cerebrovascular peripheral vascular disease and to methods of treating such disease in the human or animal body, by administering a therapeutically effective dose.
